Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In New Zealand, trastuzumab is standard therapy for human epidermal growth factor receptor-2 (HER2)-positive early and metastatic breast cancer. Given the requirement for ongoing adjuvant or maintenance treatment and intravenous (IV) delivery, such a regimen consumes considerable health care resources. The development of a subcutaneous (SC) trastuzumab formulation with a short administration time offers the potential to reduce hospital expenditure. The aim of this study was to determine medical resource utilization associated with administration of trastuzumab SC injection via handheld syringe vs trastuzumab IV infusion in patients with HER2-positive breast cancer in New Zealand. METHODS: This noninterventional, descriptive study was conducted at the outpatient oncology centers at Auckland City and Tauranga Hospitals. Trained observers recorded times associated with health care professional (HCP) tasks and consumables use associated with preparation and administration of trastuzumab IV or SC in women with early or metastatic breast cancer. The cost for each formulation was calculated as the mean cost of HCP time (based on Pharmaceutical Management Agency hourly rates) plus the mean cost of consumables used. RESULTS: Use of trastuzumab SC vs IV reduced mean chair time by 36.95 minutes and total nurse time by 6.12 minutes; there was a 20.45-minute reduction in pharmacist time when the SC formulation was used. After adding consumable costs, the overall estimated saving with trastuzumab SC vs IV was $76.94 (New Zealand dollars) per patient per cycle. CONCLUSIONS: Compared with trastuzumab IV infusion, administration of trastuzumab via SC injection reduced time spent in the clinic and decreased HCP resources and consumables needed to administer treatment. These reductions could contribute to a decrease in health care costs and an improvement in the efficiency of HER2-positive breast cancer treatment delivery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ismael, G., Hegg, R., Muehlbauer, S., Heinzmann, D., Lum, B., Kim, S.-B., Pienkowski, T., Lichinitser, M., Semiglazov, V., Melichar, B., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70329-7 · Cited by 351
Frost, G. I. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.4.4.427 · Cited by 323
Management of venous port systems in oncology: a review of current evidence
Vescia, S., Baumgärtner, A. K., Jacobs, V. R., Kiechle-Bahat, M., Rody, A., Loibl, S., & Harbeck, N. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm272 · Cited by 264
Pivot, X., Gligorov, J., Müller, V., Barrett-Lee, P., Verma, S., Knoop, A., Curigliano, G., Semiglazov, V., López-Vivanco, G., Jenkins, V., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70383-8 · Cited by 230
Rule, S., Collins, G. P., & Samanta, K. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.914033 · Cited by 66
Kruse, G. B., Amonkar, M. M., Smith, G., Skonieczny, D. C., & Stavrakas, S. (2008) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2008.14.9.844 · Cited by 44
Cited by
Anderson, K. C., Landgren, O., Arend, R. C., Chou, J., & Jacobs, I. A. (2019) · Future Oncology · doi:10.2217/fon-2019-0368 · Cited by 69
McCloskey, C., Ortega, M. T., Nair, S., Garcia, M. J., & Manevy, F. (2023) · PharmacoEconomics - Open · doi:10.1007/s41669-022-00361-3 · Cited by 66
Lopez-Vivanco, G., Salvador, J., Diez, R., López, D., De Salas-Cansado, M., Navarro, B., & De la Haba-Rodríguez, J. (2017) · Clinical and Translational Oncology · doi:10.1007/s12094-017-1684-4 · Cited by 54
Hedayati, E., Fracheboud, L., Srikant, V., Greber, D., Wallberg, S., & Linder Stragliotto, C. (2019) · PLOS ONE · doi:10.1371/journal.pone.0211783 · Cited by 39
Franken, M. G., Kanters, T. A., Coenen, J. L., de Jong, P., Koene, H. R., Lugtenburg, P. J., Jager, A., & Uyl-de Groot, C. A. (2018) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000648 · Cited by 37
O'Brien, G. L., O'Mahony, C., Cooke, K., Kinneally, A., Sinnott, S.-J., Walshe, V., Mulcahy, M., & Byrne, S. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.01.011 · Cited by 29
Farolfi, A., Silimbani, P., Gallegati, D., Petracci, E., Schirone, A., Altini, M., & Masini, C. (2017) · Oncotarget · doi:10.18632/oncotarget.18527 · Cited by 19
Despiau, F., Zagala, Y., Delord, J.-P., Montastruc, M., Lacaze, J.-L., Ferrand, R., & Bombail, M. (2017) · Bulletin du Cancer · doi:10.1016/j.bulcan.2017.08.007 · Cited by 4
Metadata
- Authors
- Ryan, S., North, R., Harvey, V., & Cox, L.
- Venue
- ClinicoEconomics and Outcomes Research
- Publisher
- Informa UK Limited
- Published
- 2015-07
- Volume
- 7
- Pages
- 423
- ISSN
- 1178-6981 (ISSN-L)
- OpenAlex
- W2117922713
- Cited by
- 39
- References
- 6
- FWCI
- 8.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.